Boston Scientific develops minimally invasive medical devices used in cardiovascular, electrophysiology, endoscopy, urology, and other procedures. Its products include cardiac mapping and ablation technologies, stents, structural-heart devices, and endoscopic tools. The company sells implantable and disposable devices and procedural technologies to hospitals and physicians worldwide.
Boston Scientific Corp. (BSX) has a MarketKingdoms composite score of 55.7 (C+), an C-range rating. It ranks 1544th of 1,866 covered companies, 73rd of 78 in Healthcare (sector average 64.5) and 10th of 10 in Medical Devices. Scores as of 2026-10-25.
Its strongest lenses are Industry opportunity at 77 (Healthcare average 81) and Stock selection at 70 (Healthcare average 79). Its weakest lenses are Trend (momentum) at 6 (sector average 50) and Expansion (growth) at 52 (sector average 50).
| Lens | Type | BSX | Healthcare average | Medical Devices average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 77 | 81 | 77 | 44th |
| Stock selection | Research signal | 70 | 79 | 78 | 12th |
| KPI momentum | Research signal | 62 | 78 | 75 | 16th |
| Catalyst watch | Research signal | 68 | 74 | 75 | 13th |
| Price (valuation) | Fundamental lens | 69 | 50 | 54 | 78th |
| Expansion (growth) | Fundamental lens | 52 | 50 | 57 | 67th |
| Quality (profitability) | Fundamental lens | 55 | 50 | 53 | 62nd |
| Trend (momentum) | Fundamental lens | 6 | 50 | 27 | 6th |
The most recent call analysed was held on 2026-07-29 (fiscal 2026 Q2). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is -17.4%: its price is well below the path its market, sector and industry moves explain (strongly undervalued versus the model path). Factor sensitivity: market beta 1.35, sector beta 0.39, industry beta 0.88; the factor model explains 46% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| DexCom Inc. (DXCM) | 70.2 | B+ | -25.0% |
| Edwards Lifesciences Corp. (EW) | 63.9 | B- | +1.7% |
| STERIS plc (STE) | 63.9 | B- | -7.7% |
| Zimmer Biomet Holdings Inc. (ZBH) | 62.7 | B- | -12.1% |
| Medtronic Plc (MDT) | 62.5 | B- | -5.9% |
| Abbott Laboratories (ABT) | 60.9 | B- | -6.4% |
| GE HealthCare Technologies Inc. (GEHC) | 60.4 | B- | -5.8% |
| Insulet Corp. (PODD) | 59.2 | B- | -18.8% |
Boston Scientific Corp. financial statements · Healthcare sector ranking · Medical Devices industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.